Nicolas Hubacz: A New Target for Stroke Recovery
Nicolas Hubacz, Research and Clinical Products Business Development Manager at Magstim, shared a post on LinkedIn about a recent article by Yan Deng et al. published in Science Signaling, adding:
”A New Target for Stroke Recovery
Stroke treatment has made tremendous progress in restoring blood flow, but many survivors are still left with lasting white matter damage, a major cause of long-term neurological disability.
A new study published in Science Signaling identifies the adenosine 2A receptor (A2AR) on microglia as a key regulator of white matter repair after ischemic stroke in mice.
The researchers found that:
- Microglia lacking A2AR showed impaired white matter regeneration after stroke, despite having similar initial injury severity.
- Activating A2AR using blood-brain barrier–permeable agonist micelles during early reperfusion enhanced remyelination and improved both cognitive and sensorimotor recovery in mice.
- A2AR activation promoted efferocytosis, allowing microglia to clear apoptotic cells and myelin debris, helping reduce secondary inflammation and create an environment that supports remyelination.
- Mechanistically, A2AR signaling triggered HIF1α-dependent metabolic reprogramming, increasing glycolysis to provide the energy needed for sustained debris clearance.
While these findings are currently limited to preclinical models, they identify microglial A2AR signaling as a potential therapeutic target for promoting white matter repair and improving functional recovery after stroke.
Paper: Adenosine 2A receptor drives microglial efferocytosis to accelerate white matter repair and functional recovery after stroke (Science Signaling, 2026)”
Title: Adenosine 2A receptor drives microglial efferocytosis to accelerate white matter repair and functional recovery after stroke
Authors: Yan Deng, Qian He, Bolin Yao, Xiang Chen, Guangli Cheng, Minhua Xu, Jiachun Hu, Luis Graca, Xiao Zhu, Xiao-Yong Zhang, Yan You, Cong Li.
Other posts featuring Nicolas Hubacz on Hemostasis Today.
-
Aug 16, 2026, 06:19Dennis Wolf: Is ZEUS the End of Anti-Inflammatory Therapy in Atherosclerosis?
-
Aug 15, 2026, 19:30José Luis Neyro: E4 and DRSP Reduce Hirsutism While Showing Comparable Effects on Thrombin Generation
-
Aug 15, 2026, 19:27Mahmoud Akraym: Don’t Choose Anticoagulation as the Immediate Treatment for Unstable AF
-
Aug 15, 2026, 19:25Ahmed Bennis: DOACs Increase 1-Year Stroke Risk but Reduce MI Risk Compared With Warfarin
-
Aug 15, 2026, 19:24Megan Adediran: An Unwavering Fight for People Living With Haemophilia
-
Aug 15, 2026, 19:23Intravenous Anticoagulation Linked to Worse Early Outcomes After Noncardioembolic Stroke – International Journal of Stroke
-
Aug 15, 2026, 18:03Alejandro González Veliz: Pulmonary Embolism Is Not Always an Anticoagulation-Only Problem
-
Aug 15, 2026, 17:57Ayesha Zia: A New Foundation for Pediatric Pulmonary Embolism Research and Care
-
Aug 15, 2026, 17:21Bilal Salman։ NETosis as a Therapeutic Target in Inflammation and Thrombosis